Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People with Diabetes Using All Types of Insulin

Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin

Analysts expect earnings to increase 22% this year and 38% in 2024. The post DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?

DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?

Tesla

DexCom and Tesla have become profitable in recent years as their sales have soared. The two are focused on growing industries -- diabetes care and electric vehicles.

2 Stocks That Turned $40,000 Into $1 Million in 10 Years

Airbnb

History shows that patient investors can reap rewards by consistently putting money to work. DexCom controls a notable slice of the diabetes care industry and is raking in profits.

A Nasdaq Bull Market Is Coming: 2 Fantastic Stocks to Buy and Hold

Abbott Labs

Edwards Lifesciences

Edwards Lifesciences' state-of-the-art heart valves have a big growth runway. Abbott Laboratories has received several encouraging FDA approvals recently.

3 No-Brainer Medical Device Stocks to Buy Right Now

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.

Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time

Chewy

Not all growth-oriented businesses are created equal, and some are continuing to thrive even now. DexCom is reaching more and more users than ever, but its addressable, untapped market opportunity is still massive.

2 Explosive Growth Stocks to Buy in April

Intuitive Surgical

While high inflation is pressuring the market, many healthcare businesses remain resilient. DexCom has a long runway for growth as the need for diabetes treatment expands.

2 All-Weather Stocks to Buy Without Hesitation Right Now

DexCom plans to keep rolling out key new devices in the next year. The company should continue growing its revenue and installed base.

Where Will DexCom Be in 1 Year?

Albemarle

Ceridian HCM Holding Inc.

Enphase Energy

Fortinet

ServiceNow

NVIDIA

Paycom Software

Take-Two Interactive Software

Following an 18% decline for the S&P 500 index (with dividends reinvested) in 2022 and a volatile and disappointing pullback from this year's stock-market rebound that crested early in February, some investors may need to be reminded about how well patience can be rewarded.

11 stocks in the S&P 500 expected to form an exclusive growth club for investors

Vertex Pharmaceuticals

The Nasdaq Composite index has been down for over a year now, but some of its components are soaring. Vertex Pharmaceuticals is the only drugmaker selling lifesaving treatments for patients who inherit a lethal disorder.

Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend

Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.

Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada

Still caught in a wide performance range, it is beginning to show signs of price improvement. The post Dexcom Stock Option Trade Could Return $465 While Risking Just $35 appeared first on Investor's Business Daily.

Dexcom Stock Option Trade Could Return $465 While Risking Just $35

Alphabet

Healthcare and technology are two industries that are set to witness explosive growth. DexCom is raking in profits, and its market opportunity is still heavily underpenetrated.

Have $1,000? 2 Stock-Split Companies to Add to Your Buy Basket Right Now.

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. Expanding coverage for rtCGM to include all eligible patients with type 1 or type 2 diabetes establishes Manitoba as the leader among Canadian provinces.

Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors

DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the overall diabetes market is expanding.

DexCom: Riding The Growth Wave

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article: “Dexcom does not have material exposure to the developments at Silicon Valley Bank, including with respect to the company's cash deposits. Although the company has worked successfully with SVB for many years, Dexcom does not have any exclusive banking relationship with SVB.

DexCom Comments on SVB Relationship

DocuSign

Edgio Inc

SVB Financial Group

Sprout Social

Upstart Holdings

Silicon Valley Bank required some clients to agree to exclusivity clauses, disabling them from diversifying where they held their money, SEC records show.

Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify

Healthcare businesses tend to remain resilient even amid economic turmoil. Vertex could soon have another blockbuster on its hands, and its existing portfolio remains strong.

2 Top Stocks to Buy in March and Hold Forever

MercadoLibre

The stock market ended mildly mixed Monday, but early gains faded and small-cap stocks lagged badly. MercadoLibre cleared a new entry.

Stock Market Cedes Early Gains Ahead Of Powell Testimony; MercadoLibre Clears New Entry, But Dexcom Plunges

Dexcom stock toppled Monday after the FDA cleared Abbott Laboratories to pair its body-worn glucose monitors with automated insulin pumps. The post Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories appeared first on Investor's Business Daily.

Dexcom Pummeled On A New FDA Clearance For Key Rival Abbott Laboratories

This company could keep going up, but beware of the risks.

1 High-Flying Growth Stock With 19% Upside, According to Wall Street

Dexcom stock popped Thursday after CMS said it would cover continuous glucose monitors for a broader group of type 2 diabetics. The post Dexcom Nears Breakout On A Surprise Medicare Decision For Its Devices appeared first on Investor's Business Daily.

Dexcom Nears Breakout On A Surprise Medicare Decision For Its Devices

Even a modest investment in great companies can pay off over the long run.

Where to Invest $1,000 in a 2023 Nasdaq Bear Market

Apple

The continuous glucose monitoring market could heat up.

News for DexCom Stock (DXCM)